Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics entities : Allogene therapeutics, inc. save search
Allogene Therapeutics Announces Q2 Investor Conference Participation
Published: 2024-04-09 (Crawled : 13:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.5%
H: 3.01%
C: 3.01%
conference therapeutics
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -1.0%
H: 9.89%
C: 4.72%
business year update therapeutics financial results
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Published: 2024-03-12 (Crawled : 12:30) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -0.39%
H: 1.78%
C: -3.16%
disease biotechnologies global therapeutics agreement platform
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Published: 2024-03-05 (Crawled : 13:30) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -0.37%
H: 3.4%
C: -0.74%
report business year update therapeutics financial results
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Published: 2024-02-28 (Crawled : 14:00) - biospace.com/
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -0.58%
H: 5.28%
C: 0.2%
conference health care therapeutics
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Published: 2024-02-16 (Crawled : 13:30) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -1.41%
H: 1.33%
C: -2.04%
asia therapeutics financial
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Published: 2024-01-16 (Crawled : 21:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -2.24%
H: 8.82%
C: 2.94%
therapeutics
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -17.4%
H: 4.64%
C: 4.11%
first trial therapeutics platform
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -17.4%
H: 4.64%
C: 4.11%
partnership first diagnostic in-vitro diagnostics trial therapeutics
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 21:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.6%
H: 2.69%
C: 1.19%
conference therapeutics platform
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
| Email alert
Add to watchlist
allo-647 meeting therapeutics
Allogene Therapeutics Announces Participation in December Investor Conference
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -0.43%
H: 8.97%
C: 7.69%
conference therapeutics
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
CLLS | $2.48 0.81% 0.4% 15K
|
Health Technology
|
| O: 0.72%
H: 0.36%
C: -14.03%
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.0%
H: 3.8%
C: 3.8%
financial
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 5.39%
H: 16.45%
C: 11.82%
candidate cancer preclinical immunotherapy meeting therapeutics
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 5.39%
H: 16.45%
C: 11.82%
cancer preclinical immunotherapy meeting therapeutics
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
Published: 2023-11-02 (Crawled : 13:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 1.77%
H: 4.51%
C: 3.13%
meeting therapeutics
Allogene Therapeutics Announces Participation in November Investor Conferences
Published: 2023-10-30 (Crawled : 13:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 1.58%
H: 9.73%
C: 7.39%
therapeutics
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.75%
H: 1.87%
C: -1.49%
report therapeutics financial results
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
Published: 2023-10-16 (Crawled : 12:30) - globenewswire.com
PRGO | $29.94 -0.33% 0.0% 970K
|
Health Technology
|
| O: 0.75%
H: 2.79%
C: 2.47%
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.31%
H: 1.56%
C: 1.25%
therapeutics financial
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2023-09-27 (Crawled : 13:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 1.19%
H: 3.09%
C: -0.29%
cancer immunotherapy meeting therapeutics platform
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.